Pursuant to Regulation 24A of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Secretarial Compliance Report issued by Mr. Vishal ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries has submitted its Annual Secretarial Compliance Report for FY2024-25, certifying compliance with SEBI regulations including listing, insider trading, takeover, and depositories rules. During the year, the company issued 9,00,000 convertible warrants (later 90,00,000 post share split) at Rs. 169.83 per share, and reduced face value from Rs. 10 to Rs. 1 via a stock split. No buyback, debenture redemption, ESOP issuance, or auditor resignation occurred. No actions, penalties, or fines were imposed by SEBI or stock exchanges, though a pending enquiry from FY2023-24 continued into this year. No director was disqualified, all policies are in place, and this is the company's first such report so there are no prior observations to act on.
For shareholders, this is a routine regulatory filing confirming the company meets its listing and governance obligations. The warrant issuance and share split could lead to higher share count and potential dilution if warrants are exercised, but no immediate price-moving action is implied.